Featured news from NHIVNA
HIV-related news from NAM
Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients
Keith Alcorn, 2015-04-25 19:20:00
The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in HIV coinfected people, and a 16-week course of treatment with ribavirin was highly effective even in the hardest-to-treat groups of treatment-experienced patients, two studies presented this week at the International Liver Congress in Vienna show.
Grazoprevir (a NS3/4 protease inhibitor) and elbasvir (a NS5A inhibitor) are being developed by Merck. The combination is being studied as a once-daily, single-tablet regimen, with or without ribavirin. The two drugs are active against multiple genotypes of hepatitis C.
Source:1
